Loading
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Regular session
$8.92
−$0.12 · -1.33%
Regular session · ET · Market data may be delayed.
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Day range
Current $8.92
52-week range
Current $8.92
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
72
Undervalued
Sentiment
64
Bullish
Risk
69
High Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Day range
Current $8.92
52-week range
Current $8.92
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.22M USD | — | — | — | — |
| Cost of goods sold | 1.92M USD | — | — | — | — |
| Gross profit | 8.3M USD | — | — | — | — |
| Research and development | 1.87M USD | 3.92M USD | 5M USD | 11.85M USD | 10.16M USD |
| Selling, general, and administrative | 29.08M USD | 7.32M USD | 4.69M USD | 5.44M USD | 4.31M USD |
| Operating expenses | 30.97M USD | 11.86M USD | 9.62M USD | 18.09M USD | 14.74M USD |
| Interest income | 1.9M USD | 161.66K USD | 6.8K USD | 2.59K USD | 2.64K USD |
| Interest expense | — | 185.78K USD | 67.71K USD | 232.29K USD | 673.13K USD |
| Depreciation and amortization | 58.57K USD | 81.22K USD | 84.48K USD | 122.17K USD | 114.55K USD |
| Operating income | −22.66M USD | −11.86M USD | −9.62M USD | −18.09M USD | −14.74M USD |
| Net income | −20.67M USD | −14.64M USD | −13.77M USD | −16.28M USD | −24.91M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
